1-Year Follow up to the 1473-IMIQ Study

A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00114023

Enrollment

Registered

2005-06-14

Start date

2005-01-31

Completion date

Unknown

Last updated

2007-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keratosis

Keywords

AK, Imiquimod 5% cream, 3M Pharmaceuticals, Aldara, Actinic Keratosis

Brief summary

This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.

Interventions

DRUGImiquimod 5% cream

Study design

Observational model

DEFINED_POPULATION

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Subject had to participate in the 1473-IMIQ Study AND have had 100% clearance of AK lesions

Exclusion criteria

* Did not use any topical preparations in the previous treatment area within 24-hours of the scheduled visit.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026